Our news
Together with patient communities, healthcare professionals, partners and investors, we are constantly making progress on our mission.
Keep up to date with the latest stories, developments and milestones.
![image](/media/vjzjenyy/preferred-shot.jpg?width=830&height=467&v=1da8b54c26fc6f0)
Dr Denise Scots-Knight Speaks to Biotech TV
Denise Scots-Knight talks to Amy Brown at Biotech TV about progress in our clinical programs.
![image](/media/k4lby4un/_mg_5205.jpg?width=392&height=250&v=1d9e180e01cfd40)
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
14 June 2024
London, June 14, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares (“ADSs”). Each ADS is being sold at a price of $3.99 per ADS in an underwritten registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50.0 million. Each ADS represents five ordinary shares of Mereo. The net proceeds of this offering are expected to be used to fund the setrusumab program, including supply and pre-launch activities in Europe, and for working capital and other general corporate purposes. The offering is expected to close on or about June 17, 2024, subject to the satisfaction of customary closing conditions.
![image](/media/k4lby4un/_mg_5205.jpg?width=830&height=467&v=1d9e180e01cfd40)
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
NOVATO, Calif. and LONDON, UK — June 11, 2024 — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced positive 14-month results from the Phase 2 portion of the ongoing Phase 2/3 Orbit study (NCT05125809) demonstrating that, as of a May 24, 2024 data cut-off date, treatment with setrusumab (UX143) continued to significantly reduce incidence of fractures in patients with OI with at least 14 months of follow-up. Treatment with setrusumab also resulted in ongoing and meaningful improvements in lumbar spine bone mineral density (BMD) at month 12 without evidence of plateau.
![image](/media/k4lby4un/_mg_5205.jpg?width=392&height=250&v=1d9e180e01cfd40)
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
30 May 2024
London, May 30, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00am ET / 04:00pm BST.